Rallybio Merges with Candid Therapeutics in $500M+ Deal to Build Autoimmune Powerhouse

Rallybio announces a reverse merger with Candid Therapeutics, forming a new Nasdaq-listed company focused on T-cell therapies for autoimmune diseases, backed by over $500M in funding through 2030.